Compare Adaptive Biotechnologies Corp (ADPT) vs MasTec Inc (MTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs MasTec Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while MasTec Inc trades at $378.82 (market cap $30.08B). The key difference: MasTec Inc is far larger — about 9× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | MTZ | |
|---|---|---|
Market Cap | $3.33B | $30.08B |
Sector | Health | Technology |
52-Week High | $22.37 | $437.51 |
52-Week Low | $10.24 | $168.24 |
Enterprise Value | $3.19B | $32.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MTZ trades at $380.63, up 1.93% today, with a neutral technical signal. The stock shows strong fundamental momentum, beating earnings estimates in three consecutive quarters, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of Superior Group to expand data center infrastructure capabilities, positioning the company for growth in AI-driven demand.
Outlook remains positive with 89% analyst buy ratings and a $476.62 consensus price target, implying 25% upside. Key risks include integration challenges from acquisitions and execution risks on large projects. Revenue growth is supported by infrastructure spending trends, but valuation multiples are elevated relative to industry peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
